Brian A Mendelsohn

List of Publications by Year
in descending order

29 papers	2,446 citations	394421 19 h-index	526287 27 g-index
31 all docs	31 docs citations	31 times ranked	2347 citing authors

#	Article	IF	Citations
1	An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opinion on Biological Therapy, 2021, 21, 963-975.	3.1	42
2	Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcÎ³IIIa receptor-ligand affinity column. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1177, 122753.	2.3	21
3	In-situ Reverse Phased HPLC Analysis of Intact Antibody-Drug Conjugates. Analytical Sciences, 2021, 37, 1171-1176.	1.6	16
4	Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibodyâ€“Drug Conjugates. Molecular Pharmaceutics, 2021, 18, 4058-4066.	4.6	26
5	Recent Advances in Drugâ€“Antibody Ratio Determination of Antibodyâ€“Drug Conjugates. Chemical and Pharmaceutical Bulletin, 2021, 69, 976-983.	1.3	33
6	Insight into Temperature Dependency and Design of Experiments towards Process Development for Cysteineâ€Based Antibodyâ€Drug Conjugates. ChemistrySelect, 2020, 5, 8435-8439.	1.5	20
7	Analytical Comparison of Antibody-drug Conjugates Based on Good Manufacturing Practice Strategies. Analytical Sciences, 2020, 36, 871-875.	1.6	23
8	Synthesis and Biological Evaluation of Antibody Drug Conjugates Based on an Antibody Expression System: Conamax. ACS Omega, 2020, 5, 7193-7200.	3.5	25
9	Antibodyâ€“Drug Conjugate Payloads; Study of Auristatin Derivatives. Chemical and Pharmaceutical Bulletin, 2020, 68, 201-211.	1.3	37
10	Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibodyâ€“Drug Conjugates Produced by AJICAP First Generation Technology. Journal of the American Society for Mass Spectrometry, 2020, 31, 1706-1712.	2.8	22
11	Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1140, 121981.	2.3	23
12	Comparison of Analytical Methods for Antibodyâ€“Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP. Analytical Chemistry, 2019, 91, 12724-12732.	6.5	27
13	AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angewandte Chemie - International Edition, 2019, 58, 5592-5597.	13.8	73
14	Good Manufacturing Practice Strategy for Antibodyâ€“Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP. ACS Omega, 2019, 4, 20564-20570.	3.5	26
15	Gram-Scale Antibodyâ€“Drug Conjugate Synthesis by Site-Specific Chemical Conjugation: AJICAP First Generation. Organic Process Research and Development, 2019, 23, 2647-2654.	2.7	23
16	Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibodyâ€“Drug Conjugates. Cancer Research, 2018, 78, 2115-2126.	0.9	72
17	Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications. ACS Omega, 2018, 3, 5212-5221.	3.5	13
18	Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite. Molecular Pharmaceutics, 2018, 15, 2384-2390.	4.6	27

#	Article	IF	Citations
19	Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates. Bioconjugate Chemistry, 2017, 28, 371-381.	3.6	33
20	A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise. Molecular Cancer Therapeutics, 2017, 16, 1866-1876.	4.1	49
21	Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains. Journal of Natural Products, 2017, 80, 2484-2491.	3.0	16
22	Oxidation of Î±-Oxo-Oximes to Nitrile Oxides with Hypervalent Iodine Reagents. Journal of Organic Chemistry, 2011, 76, 728-731.	3.2	68
23	Approach to Tetrodotoxin via the Oxidative Amidation of a Phenol. Organic Letters, 2009, 11, 4736-4739.	4.6	54
24	Oxidation of Oximes to Nitrile Oxides with Hypervalent Iodine Reagents. Organic Letters, 2009, 11, 1539-1542.	4.6	195
25	Crystal structure of methyl 2-(1-acetamido-4-oxocyclohexa-2,5-dienyl)- acetate, C11H13NO4. Zeitschrift Fur Kristallographie - New Crystal Structures, 2008, 223, 205-206.	0.3	0
26	Crystal structure of N-((2aR,2a1S,3S,5aS,7R)-3,7-dihydroxy-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (2a,2a1,3,5a,6,7-hexahydroin Kristallographie - New Crystal Structures, 2008, 223, 203-204.	0.3	0
27	Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:Â Effects of Linker Technology on Efficacy and Toxicity. Bioconjugate Chemistry, 2006, 17, 114-124.	3.6	448
28	Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology, 2003, 21, 778-784.	17.5	1,018
29	Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.8	8